NASDAQ:BIOS - BioScrip Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.71 +0.01 (+0.37 %)
(As of 06/19/2018 12:25 PM ET)
Previous Close$2.70
Today's Range$2.70 - $2.72
52-Week Range$1.80 - $3.39
Volume10,151 shs
Average Volume512,680 shs
Market Capitalization$344.19 million
P/E Ratio-6.14
Dividend YieldN/A
Beta0.08
BioScrip logoBioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.

Receive BIOS News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:BIOS
CUSIP09069N10
Phone720-697-5200

Debt

Debt-to-Equity Ratio-4.79
Current Ratio1.70
Quick Ratio1.30

Price-To-Earnings

Trailing P/E Ratio-6.14
Forward P/E Ratio-8.74
P/E GrowthN/A

Sales & Book Value

Annual Sales$817.19 million
Price / Sales0.42
Cash FlowN/A
Price / CashN/A
Book Value($0.66) per share
Price / Book-4.11

Profitability

EPS (Most Recent Fiscal Year)($0.44)
Net Income$-64,190,000.00
Net Margins-9.23%
Return on EquityN/A
Return on Assets-8.77%

Miscellaneous

Employees2,154
Outstanding Shares127,950,000

BioScrip (NASDAQ:BIOS) Frequently Asked Questions

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip Inc (NASDAQ:BIOS) issued its quarterly earnings results on Thursday, May, 10th. The company reported ($0.12) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.01. The company had revenue of $168.60 million for the quarter, compared to the consensus estimate of $164.72 million. The business's revenue was down 22.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.18) earnings per share. View BioScrip's Earnings History.

When is BioScrip's next earnings date?

BioScrip is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for BioScrip.

What price target have analysts set for BIOS?

4 analysts have issued 1 year price targets for BioScrip's stock. Their forecasts range from $3.25 to $4.00. On average, they anticipate BioScrip's share price to reach $3.5625 in the next twelve months. View Analyst Ratings for BioScrip.

Who are some of BioScrip's key competitors?

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:
  • Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 53)
  • Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
  • Ms. Harriet Booker, Sr. VP & COO (Age 51)
  • Mr. Alex Schott, Sr. VP of Strategic Operations & Interim Chief Accounting Officer (Age 48)
  • Ms. Jody Kepler, Sr. VP, Chief Compliance Officer & Privacy Officer (Age 48)

Has BioScrip been receiving favorable news coverage?

News articles about BIOS stock have been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. BioScrip earned a coverage optimism score of 0.06 on Accern's scale. They also assigned media stories about the company an impact score of 47.61 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are BioScrip's major shareholders?

BioScrip's stock is owned by a number of of institutional and retail investors. Top institutional investors include Venor Capital Management LP (11.45%), Gabelli Funds LLC (8.00%), BlackRock Inc. (5.18%), Diamond Hill Capital Management Inc. (3.16%), Wynnefield Capital Inc. (2.37%) and Millennium Management LLC (1.90%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, Jeffrey M Kreger, Michael G Bronfein, R Carter Pate and Stephen Deitsch. View Institutional Ownership Trends for BioScrip.

Which institutional investors are selling BioScrip stock?

BIOS stock was sold by a variety of institutional investors in the last quarter, including Alta Fundamental Advisers LLC, California Public Employees Retirement System, Gabelli Funds LLC, UBS Group AG, Teton Advisors Inc., Wells Fargo & Company MN, Wynnefield Capital Inc. and Royal Bank of Canada. Company insiders that have sold BioScrip company stock in the last year include Coliseum Capital Management, L and Michael G Bronfein. View Insider Buying and Selling for BioScrip.

Which institutional investors are buying BioScrip stock?

BIOS stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Venor Capital Management LP, Millrace Asset Group Inc., Cambridge Investment Research Advisors Inc., GSA Capital Partners LLP, Diamond Hill Capital Management Inc. and Schwab Charles Investment Management Inc.. Company insiders that have bought BioScrip stock in the last two years include Coliseum Capital Management, L, Daniel E Greenleaf, Jeffrey M Kreger, R Carter Pate and Stephen Deitsch. View Insider Buying and Selling for BioScrip.

How do I buy shares of BioScrip?

Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BIOS stock can currently be purchased for approximately $2.71.

How big of a company is BioScrip?

BioScrip has a market capitalization of $344.19 million and generates $817.19 million in revenue each year. The company earns $-64,190,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. BioScrip employs 2,154 workers across the globe.

How can I contact BioScrip?

BioScrip's mailing address is 1600 BROADWAY SUITE 950, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected]


MarketBeat Community Rating for BioScrip (BIOS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  348
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.